Trial Profile

An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics and Safety of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amoxicillin/clavulanic acid (Primary)
Indications Bacterial infections; Community-acquired pneumonia; Rhinosinusitis
Focus Pharmacokinetics
Sponsors GlaxoSmithKline; GSK

28 Mar 2025 Planned End Date changed from 17 Jan 2024 to 8 Jul 2024.
28 Mar 2025 Planned primary completion date changed from 17 Jan 2024 to 8 Jul 2024.
28 Mar 2025 Planned initiation date changed from 23 Jun 2023 to 14 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com